SCHEMBL3560405

SCHEMBL3560405

CN(C)[C@H]1CCN(C(=O)Nc2cc(Oc3ccc(N(C(=O)C4(C(N)=O)CC4)c4ccc(F)cc4)cc3F)ccn2)C1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 15/20 0.44
BRAF P15056 6/20 0.44
MET P08581 8/20 0.44
NTRK1 P04629 2/20 0.44
EPHB6 O15197 1/20 0.44
RIPK2 O43353 1/20 0.44
ABL1 P00519 1/20 0.44
LCK P06239 1/20 0.44
LYN P07948 1/20 0.44
RET P07949 1/20 0.44
HCK P08631 1/20 0.44
PDGFRB P09619 1/20 0.44
BCR P11274 1/20 0.44
EPHA2 P29317 1/20 0.44
EPHB2 P29323 1/20 0.44
FLT3 P36888 1/20 0.44
ABL2 P42684 1/20 0.44
FRK P42685 1/20 0.44
LIMK1 P53667 1/20 0.44
EPHB3 P54753 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3556880 1.00 KDR (0.44) KDRBRAFMETNTRK1EPHB6
SCHEMBL3555866 0.96 KDR (0.46) KDRBRAFMETNTRK1EPHB6
SCHEMBL3553004 0.92 KDR (0.48) KDRBRAFMETNTRK1EPHB6
SCHEMBL3558389 0.92 KDR (0.48) KDRBRAFMETNTRK1EPHB6
SCHEMBL3560923 0.92 MET (0.49) KDRBRAFMETNTRK1EPHB6
SCHEMBL3557519 0.91 MET (0.44) KDRBRAFMETNTRK1EPHB6
SCHEMBL15006283 0.91 MET (0.44) KDRBRAFMETNTRK1EPHB6
SCHEMBL3562209 0.91 MET (0.44) KDRBRAFMETNTRK1EPHB6
SCHEMBL3612262 0.89 MET (0.46) KDRBRAFMETNTRK1EPHB6
SCHEMBL2249560 0.89 KDR (0.48) KDRBRAFMETNTRK1EPHB6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1889836-B1 NOVEL PYRIDINE DERIVATIVE AND PYRIMIDINE DERIVATIVE (3) EISAI R&D MAN CO LTD (JP) 2013-06-12 EP disclosed
US-7855290-B2 N-[4-({2-[({4-[2-(Dimethylamino)ethyl]piperazin-1-yl}carbonyl)amino]pyridin-4-yl}oxy)-2-fluorophenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide; hepatocyte growth factor receptor (HGFR) inhibitors; antitumor, -carcinogenic, -metastasis agents EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-12-21 US disclosed
US-20080319188-A1 Novel pyridine derivatives and pyrimidine derivatives (3) EISAI R&D MANAGEMENT CO., LTD. (JP) 2008-12-25 US disclosed
EP-1889836-A1 NOVEL PYRIDINE DERIVATIVE AND PYRIMIDINE DERIVATIVE (3) Eisai R&D Management Co., Ltd. (JP) 2008-02-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080319188-A1 Novel pyridine derivatives and pyrimidine derivatives (3) HGF, MET, FLT4 KDR 8/4885BRAF 56/4885MET 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.